Objectives: The genus Mycobacterium has more than 120 well-characterized species. Although the incidence of tuberculosis has decreased over the studied period, other, non-tuberculous mycobacteria (NTM) are isolated more often. Since, Mycobacterium xenopi is the most frequent NTM isolate in Croatia we studied its epidemiology and clinical relevance.

Methods: We performed a retrospective study over a 25-year period determining epidemiology, radiological findings and clinical importance of M. xenopi infection, obtaining data from archives in health care institutions from all over the country.

Results: We detected 40 patients with a positive isolate of M. xenopi. Twenty-four patients met American Thoracic Society criteria for pulmonary disease. Eighteen (90%) of treated patients were male, on average 61.7 years old. Nineteen (95%) patients lived in towns. Most of them had comorbid disease, 18 (90%), with chronic obstructive pulmonary disease (COPD) being the most frequent, found in 11 (55%) patients. All patients were immunocompetent. We found COPD as the most frequent comorbid disease in the group of patients with worse treatment response (n=8; 80%), while in patients with good treatment response COPD was less frequent (n=3; 30%). Differences in the proportions of patients with COPD were significant (p=0.037).

Conclusion: In patients with M. xenopi pulmonary infection, COPD is a predisposing condition, and as a comorbid disease, is an important prognostic factor for treatment response.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinf.2009.01.001DOI Listing

Publication Analysis

Top Keywords

pulmonary disease
12
comorbid disease
12
copd frequent
12
treatment response
12
patients
11
mycobacterium xenopi
8
xenopi pulmonary
8
epidemiology clinical
8
disease
6
copd
5

Similar Publications

COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time.

Rheumatol Int

December 2024

Department of General Practice N2, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.

We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020-2023) and compares the same with the pre-pandemic period (2016-2019). We assume that SARS-CoV-2 triggers ARD.

View Article and Find Full Text PDF

This study investigated the incidence of new-onset cardiovascular disorders up to 3.5 years post SARS-CoV-2 infection for 56,400 individuals with COVID-19 and 1,093,904 contemporary controls without COVID-19 in the Montefiore Health System (03/11/2020 to 07/01/2023). Outcomes were new incidence of major adverse cardiovascular event (MACE), arrhythmias, inflammatory heart disease, thrombosis, cerebrovascular disorders, ischemic heart disease and other cardiac disorders between 30 days and (up to) 3.

View Article and Find Full Text PDF

Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC.

Sci Rep

December 2024

Interventional Oncology, Johnson & Johnson Enterprise Innovation, Inc, 10th Floor 255 Main St, 02142, Cambridge, Boston, MA, USA.

The introduction of anti-PD-1/PD-L1 therapies revolutionized treatment for advanced non-small cell lung cancer (NSCLC), yet response rates remain modest, underscoring the need for predictive biomarkers. While a T cell inflamed gene expression profile (GEP) has predicted anti-PD-1 response in various cancers, it failed in a large NSCLC cohort from the Stand Up To Cancer-Mark (SU2C-MARK) Foundation. Re-analysis revealed that while the T cell inflamed GEP alone was not predictive, its performance improved significantly when combined with gene signatures of myeloid cell markers.

View Article and Find Full Text PDF

The aim of this study was to evaluate how COVID-19 affected acute stroke care and outcome in patients with acute ischemic or hemorrhagic stroke. We performed a retrospective analysis on patients who were admitted with acute ischemic (AIS) or hemorrhagic (ICH) stroke from September 2020 to May 2021 with and without COVID-19. We recorded demographic and clinical data, imaging parameters, functional outcome and mortality at one year.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!